In providing our
products and services, we adopt a full service approach, which
We have a regular
Our specialty in sourcing is
our full service approach which includes identification of potential
suppliers, follow-up and liaison with the suppliers and custom
manufacturing projects. Currently working with a core client base we
are doing the following:
The customer identifies an intermediate/API and would like to source in
China. PharmaVantage identifies a list of all manufacturers
providing also historical, financial, Quality and
management background to shortlist the top tier of suppliers. We
initiate the vendor approval process and arrange customers QA
audits, we follow-up on the the audit and continue to liaison
with the client through commercial purchasing ensuring timely
shipments and proper documentation. We expedite any problems and
serve as the on-going liaison between supplier and customer and
operate on a 100% transparent basis.
We develop key
intermediates for generic products already off-patent or coming
off patent. We work with our R and D associates and clients to
develop a cost effective process and identify manufacturers for
scale up to commercial scale.
on custom manufacturing projects with either technology provided
from clients or available in China.
of our full service approach, we provide our
clients with regular updates on the products they purchase from
us, in terms of pricing trends, supply changes to keep the
client abreast of changes.
pharmaceutical industry is currently undergoing rapid
changes-consolidations, mergers and acquisitions, privatization. It
is essential for success in China to have a solid channel to
suppliers to support the customer’s success in China and to minimize
the problems. Given China’s rising importance as a pharma supplier,
for most companies, the question is not if you should
be involved in China, but how to develop a successful
strategy. PharmaVantage can provide the solution.
pharmaceutical market is quite different from that of the West and
selling to China requires identification of products, sales
strategy, customers and distribution channels. Sales to China
require also an
Import Drug License (IDL)
preparation and translation of the application dossier. We have a
team devoted to product registration and fifteen years experience.
As part of our
“full service” approach, we offer registration services in
conjunction with sales and marketing of the product in China. We
have strong ties with the State Food and Drug Administration (SFDA),
the Coastal Inspection Institutes, the National Institute for the
Control of Pharmaceutical and Biological Products and the Center for
Drug Evaluation—the key organizations involved in product
China is a huge
pharmaceutical market estimated at USD 19 billion in the first half
of 2004. Entrance into WTO has enhanced opportunities for foreign
products through lowering of import tariffs and leveling of the
playing field through greater transparency in the IDL process.
Generic products represent over 45% of the total market. With
increasing disposable income and greater consumer awareness, there
are opportunities for more sophisticated drug delivery products,
pediatric formulations as well as nutritional supplements and OTC
from abroad is also of increasing interest by the Chinese pharma
firms interested to rapidly expand their product portfolios.
drugs in China are not the blockbusters of the West. China is a
unique market. While currently primarily a branded generic market,
sales are dependent on devising unique marketing and promotional
activities and the panache western drugs continue to have in China
provides additional opportunities for Westerners.
We can assist in
the identification of products, registration, sales and marketing in
have undertaken a variety of consultancy projects for both
multinational pharmaceutical companies, generic companies and
nutritional supplement companies.
We are also under
retainer to several firms to provide updates on production
capabilities and pricing for a targeted product type.
Recent studies for
production/pricing in past two years
trends in semisynthetic antibibiotics 2002-2003
Top ten selling
opthamalic products in China, producers and sales volume
potential production of two proprietary anti-viral products
nutritional supplements process and time-line
Production/pricing in China 2004 for two generic veterinary
potential JV partners for major USA OTC producer
We have supplied
reports to clients to support their own research or to serve as the
basis for additional research in China. Consulting is a smaller part
of our sourcing/sales strategy but as we have acquired in our twenty
years experience a substantial database can readily access
information on manufacturers and products. We have also assisted on
an ad hoc basis for clients general problem resolution with respect
to clients business activities in China.